Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Susana Banerjee"'
Autor:
Jarushka Naidoo, Maria L Ascierto, Matthew D Hellmann, Ding Wang, Susana Banerjee, Mayukh Das, Panagiotis Kourtesis, Jennifer R Diamond, Teresa Alonso-Gordoa, Sandip P Patel, Nathan E Standifer, Doug C Palmer, Lin-Yang Cheng, Benedito A Carneiro
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background The combination of monalizumab (anti-NKG2A/CD94) and durvalumab (anti-programmed death ligand-1) may promote antitumor immunity by targeting innate and adaptive immunity. This phase 1/2 study of monalizumab and durvalumab evaluated safety,
Externí odkaz:
https://doaj.org/article/53d0d5cbaca340b3995a64a938291778
Autor:
Ana Oaknin, Maria-Pilar Barretina-Ginesta, Victor Moreno, Thierry André, Ruth Plummer, Florence Joly, Rowan Miller, Joanna Pikiel, Susana Banerjee, Jose Manuel Trigo Perez, Bhavana Pothuri, Andrea Jewell, Anna Tinker, Dominique Berton, Susan Ellard, Jennifer Veneris, Tao Duan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/d39ea0b42267479e959567a5b2a0f1fd
Autor:
Tao Duan, Ana Oaknin, Maria-Pilar Barretina-Ginesta, Andrea Jewell, Bhavana Pothuri, Joanna Pikiel, Victor Moreno, Thierry André, Anna V. Tinker, Susana Banerjee, Giuseppe Curigliano, Susan Ellard, Jennifer Taylor Veneris, Ruth Plummer, Florence Joly, Dominique Berton, Rowan Miller, Jose Manuel Trigo Perez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundDostarlimab is a humanized programmed death 1 (PD-1) receptor monoclonal antibody that blocks interaction with the ligands PD-L1 and PD-L2. Dostarlimab is approved as a monotherapy in adult patients (pts) with mismatch repair deficient (dMM